Novavax
NVAX
#5331
Rank
โ‚น146.30 B
Marketcap
โ‚น889.72
Share price
1.30%
Change (1 day)
74.71%
Change (1 year)

Revenue for Novavax (NVAX)

Revenue in 2025 (TTM): โ‚น93.50 Billion

According to Novavax's latest financial reports the company's current revenue (TTM ) is โ‚น103.07 Billion. an increase over the revenue in the year 2024 that were of โ‚น58.52 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Novavax from 1996 to 2025

Annual revenue

Year Revenue Change
2025 โ‚น97.23 B66.15%
2024 โ‚น58.52 B1.37%
2023 โ‚น57.72 B-49.93%
2022 โ‚น115.30 B35.14%
2021 โ‚น85.31 B145.3%
2020 โ‚น34.78 B2513.63%
2019 โ‚น1.33 B-44.49%
2018 โ‚น2.39 B20.44%
2017 โ‚น1.99 B90.8%
2016 โ‚น1.04 B-56.69%
2015 โ‚น2.40 B23.98%
2014 โ‚น1.94 B50.39%
2013 โ‚น1.29 B6.89%
2012 โ‚น1.20 B55.56%
2011 โ‚น0.77 B4955.33%
2010 โ‚น15.36 M1.92%
2009 โ‚น15.08 M-70.51%
2008 โ‚น51.14 M-0.14%
2007 โ‚น51.21 M-75.31%
2006 โ‚น0.20 B-37.61%
2005 โ‚น0.33 B-13.98%
2004 โ‚น0.38 B-27.98%
2003 โ‚น0.53 B-21.22%
2002 โ‚น0.68 B-41.34%
2001 โ‚น1.16 B905.27%
2000 โ‚น0.11 B121.43%
1999 โ‚น52.16 M75.27%
1998 โ‚น29.76 M26.23%
1997 โ‚น23.57 M118.64%
1996 โ‚น10.78 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Novartis
NVS
โ‚น5.383 T 5,123.43%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Pfizer
PFE
โ‚น6.024 T 5,745.32%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
โ‚น5.751 T 5,479.89%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
โ‚น4.202 T 3,977.40%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sarepta Therapeutics
SRPT
โ‚น209.17 B 102.95%๐Ÿ‡บ๐Ÿ‡ธ USA
Celldex Therapeutics
CLDX
โ‚น0.14 B-99.86%๐Ÿ‡บ๐Ÿ‡ธ USA
Agenus
AGEN
โ‚น10.16 B-90.14%๐Ÿ‡บ๐Ÿ‡ธ USA
NanoViricides
NNVC
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
BioCryst Pharmaceuticals
BCRX
โ‚น83.24 B-19.23%๐Ÿ‡บ๐Ÿ‡ธ USA
Emergent BioSolutions
EBS
โ‚น71.43 B-30.69%๐Ÿ‡บ๐Ÿ‡ธ USA